Search
G207
go.drugbank.com/drugs/DB05827InvestigationalMediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans. … G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG.
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10774ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10775ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10792ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB11034ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB11035ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
go.drugbank.com/drugs/DB11037ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11041ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.